Increased Bone Mineral Density (Bmd) In Postmenopausal Women With Osteoporosis (Op) Receiving Two Denosumab Injections In Routine Clinical Practice In Bulgaria.
نویسندگان
چکیده
• Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increase in bone fragility and the risk of fractures. • In Bulgaria, denosumab 60mg subcutaneous is prescribed for the treatment of postmenopausal osteoporosis (PMO) by specialists (endocrinologists and rheumatologists) and reimbursed for patients with a T-score ≤ -2.5 at one or more skeletal sites, measured with Dual-energy X-ray Absorptiometry (DXA) once yearly. • The objective of the study was to describe baseline characteristics and changes in BMD T-scores at 1 year, in postmenopausal women with osteoporosis (OP) receiving 2 denosumab injections once every 6 months in routine clinical practice in Bulgaria. INTRODUCTION
منابع مشابه
Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice
BACKGROUND Postmenopausal osteoporosis (PMO) is common among women over 50 years of age and is associated with an increased risk of fracture. Bone-targeted agents, such as denosumab, can reduce fracture risk in patients with PMO. OBJECTIVE The aim was to describe baseline characteristics and changes in bone mineral density (BMD) T-scores among women with PMO receiving denosumab in Bulgaria. ...
متن کاملMedication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Persistence with osteoporosis therapy is critical for fracture risk reduction. This observational study evaluated medication-taking behaviour of women with postmenopausal osteoporosis receiving denosumab or oral ibandronate in real-world clinical practice in Bulgaria. Compared with ibandronate, densoumab was associated with a lower discontinuation rate and greater increases in bone mineral dens...
متن کاملDenosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment
Osteoporosis is a key health problem in postmenopausal women with high social and economic impact. Decreased bone mineral density (BMD) and deterioration of bone microarchitecture may occur also as a result of long-term glucocorticoid treatment (GCT) of autoimmune or inflammatory conditions. Denosumab specifically inhibits the binding of the receptor activator of nuclear factor-κB to its ligand...
متن کاملBone mineral density loss in postmenopausal onset rheumatoid arthritis is not greater than premenopausal onset disease
Background: Postmenopausal onset rheumatoid arthritis (post-RA) is expected to have greater bone mineral density (BMD) loss than premenopauasal onset (pre-RA) due to estrogen deficiency and aging. This study aimed to compare the BMD status of the two RA groups with age-matched non-RA controls. Methods: The patients with RA on follow-up examination were stratified according to age of onset. ...
متن کاملBone mineral density loss in postmenopausal onset rheumatoid arthritis is not greater than premenopausal onset disease
Abstract Background: Postmenopausal onset rheumatoid arthritis (post-RA) is expected to have greater bone mineral density (BMD) loss than premenopauasal onset (pre-RA) due to estrogen deficiency and aging. This study aimed to compare the BMD status of the two RA groups with age-matched non-RA controls. Methods: The patients with RA on follow-up examination were stratified according to age...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014